Comparative Pharmacology
Head-to-head clinical analysis: LUPRON versus LUTREPULSE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON versus LUTREPULSE KIT.
LUPRON vs LUTREPULSE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary gonadotropin secretion, leading to decreased testosterone and estradiol levels.
LUTREPULSE (gonadorelin acetate) is a synthetic decapeptide analog of endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on the anterior pituitary gonadotroph cells, stimulating synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In males, LH stimulates Leydig cells to produce testosterone; in females, LH triggers ovulation and FSH stimulates follicular development.
3.75 mg intramuscularly once monthly or 11.25 mg intramuscularly once every 3 months. For endometriosis, 3.75 mg intramuscularly monthly for up to 6 months. For central precocious puberty, 0.3 mg/kg intramuscularly every 28 days.
5 mcg subcutaneously every 90 minutes via pulsatile pump.
None Documented
None Documented
Terminal half-life approximately 3 hours after subcutaneous administration; in patients with renal impairment, half-life may be prolonged
3 hours (initial phase), terminal elimination half-life 10-12 hours; clinically, steady-state reached within 2 days.
Renal (primarily as metabolites), <5% unchanged; fecal ~5%
Renal: 10% unchanged; hepatic metabolism, metabolites primarily excreted in bile (70%) and feces.
Category C
Category C
GnRH Agonist
GnRH Agonist